US equities
|
NVDA
$236.76
▲+1.20%
MU
$1,064.01
▼-1.01%
INTC
$116.83
▼-2.10%
SPCX
$161.88
▲+1.84%
MSFT
$527.70
▲+1.96%
TSLA
$369.12
▼-0.40%
AMD
$628.40
▼-0.87%
SNDK
$1,729.00
▲+0.52%
NVDA
$236.76
▲+1.20%
MU
$1,064.01
▼-1.01%
INTC
$116.83
▼-2.10%
SPCX
$161.88
▲+1.84%
MSFT
$527.70
▲+1.96%
TSLA
$369.12
▼-0.40%
AMD
$628.40
▼-0.87%
SNDK
$1,729.00
▲+0.52%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tempest Therapeutics, Inc. - Common Stock
(NQ:
TPST
)
0.8250
+0.0150 (+1.85%)
Delayed Quote
Updated: 9:36 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tempest Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 23, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
August 21, 2024
Expansion of leadership team to strengthen global clinical expertise
From
Tempest Therapeutics
Via
GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
↗
August 15, 2024
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...
Via
Benzinga
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
August 15, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
↗
August 09, 2024
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
↗
July 05, 2024
Via
Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
↗
June 20, 2024
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
June 20, 2024
Via
Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
↗
June 20, 2024
Via
Benzinga
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
↗
June 20, 2024
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...
Via
Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
↗
June 20, 2024
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.
Via
InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
↗
June 20, 2024
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.
Via
InvestorPlace
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2024
Via
Benzinga
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
↗
June 20, 2024
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 20, 2024
Via
Benzinga
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
June 20, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 20, 2024
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 19, 2024
Via
Benzinga
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
June 18, 2024
Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
May 31, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Tempest to Participate in Upcoming Investor Conferences
May 21, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024
↗
May 09, 2024
TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 26, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
April 09, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 05, 2024
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Via
Benzinga
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
April 04, 2024
From
Tempest Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
